5. Methods of disease treatment with pyrethroids. 1. Claim 1: a formula compound (1),Or a pharmaceutically acceptable salt, wherein a is arilo or isobutylene, arilo or isobutylene can be selectively substituted, arilo or isobutylene can be selectively mixed with a selectively substituted carbocyclo or a selectively substituted isopropene； X from - nh-s (o) 8322 -；-S (O) -NH--NH-S (O) -CH --0-0-0-0-0-NH-S (O) -CH --NH-S (O) -,-S (O) -NH-o -CH -S (O) -NH-This is C (H) or N, if there are no more than two groups, and it is n； R1 7491 is hydroxy -, ch8322；, oh -, CHO -, co8322；, n (r18304；), 74912222；-CO₂-alkyl Cilo,-OP (3DO) (OH) u -OCO -CH -OP (3DO) (OH)R¹ᵇ is C₁₋₈ alkyl optionally substituted by one to four R⁵ groups；a. Alquenilo c83218d8331i8328 was selectively replaced by one to four r83099 groups；Propyl propyl propyl propyl propyl propyl propyl propyl propyl propyl propyl propyl 1. It can be replaced by cyclomethylcla, isocyclopentadiene, isocyclopentadiene, isocyclopentadiene, aralquilo, aralquenilo, isopropyl or isopropyl； each R2 is selected separately among halogen, asphalt, CN, oh and alcoxi, where the tar or alcoxi can be replaced by 1-4 r83099 groups；or two adjacent R² groups are taken together with the ring atoms to which they are attached to form a 5- to 6-membered carbocyclic, aryl, heterocyclic or heteroaryl ring； each R⁴ is independently selected from halo, alkyl, alkoxy, haloalkyl, haloalkoxy and hydroxyl； each R⁵ is independently selected from halo, OH, C₁₋₆ alkoxy,CN, NH₂,-SO₂-alkyl C₁₋₆,-NH (apartment c8332131) and n (apartment c8332131) 832222；each R¹⁰ᵃ is independently selected from hydrogen or C₁₋₆-alkyl；N is equal to 0, 1, 2 or 3； m is equal to 0, 1 or 2； provided that a formula compound (1) is not (I) 4 - [[4-hydroxi-4 - (4-metallic) - 1-pipelining] carbon] - n-2-tiazoii-benzensalfonada； (II) 4 - [[4 - (4-chlorophenyl) - 4-hydroxi-1-pipelining] - carbon] - n-2-tiazoli-benzentalf-mida； (III) 4 - [[4 - (3-fluoronil) - 4-hydroxi-1-piperidinil] - c
